[HTML][HTML] Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 …
B Williams, TM MacDonald, SV Morant… - The lancet Diabetes & …, 2018 - thelancet.com
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
[HTML][HTML] Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 …
B Williams, TM MacDonald, SV Morant… - The Lancet. Diabetes …, 2018 - ncbi.nlm.nih.gov
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
[PDF][PDF] Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …
B Williams, TM MacDonald, SV Morant, DJ Webb… - 2018 - research.ed.ac.uk
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
[PDF][PDF] Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …
B Williams, TM MacDonald, SV Morant… - LANCET DIABETES …, 2018 - qmro.qmul.ac.uk
Background In the PATHWAY-2 study of resistant hypertension (RHTN), spironolactone
lowered bloodpressure (BP) substantially more than conventional antihypertensive drugs …
lowered bloodpressure (BP) substantially more than conventional antihypertensive drugs …
[PDF][PDF] Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …
B Williams, TM MacDonald, SV Morant, DJ Webb… - 2018 - core.ac.uk
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …
B Williams, TM MacDonald… - The Lancet …, 2018 - discovery.dundee.ac.uk
Background: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
[HTML][HTML] Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 …
B Williams, TM MacDonald, SV Morant… - The lancet. Diabetes …, 2018 - europepmc.org
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …
B Williams, TM MacDonald, SV Morant… - Lancet Diabetes and …, 2018 - eprints.gla.ac.uk
Background: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …
B Williams, TM MacDonald, SV Morant… - Lancet Diabetes …, 2018 - discovery.ucl.ac.uk
BACKGROUND: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …
[PDF][PDF] Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …
B Williams, TM MacDonald, SV Morant, DJ Webb… - 2018 - pure.ed.ac.uk
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …
blood pressure substantially more than conventional antihypertensive drugs. We did three …